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ABSTRACT
Skin cancer, including both melanoma and
non-melanoma, is the most common type of
malignancy in the Caucasian population.
Firstly, we review the evidence for the
observed increase in the incidence of skin
cancer over recent decades, and investigate
whether this is a true increase or an artefact
of greater screening and over-diagnosis.
Prevention strategies are also discussed.
Secondly, we discuss the complexities and
challenges encountered when diagnosing and
developing treatment strategies for skin cancer.
Key case studies are presented that highlight the
practic challenges of choosing the most
appropriate treatment for patients with skin
cancer. Thirdly, we consider the potential risks
and benefits of increased sun exposure.
However, this is discussed in terms of the
possibility that the avoidance of sun exposure
in order to reduce the risk of skin cancer may be
less important than the reduction in all-cause
mortality as a result of the potential benefits of
increased exposure to the sun. Finally, we
consider common questions on human
papillomavirus infection.
Keywords: Dermatology; Diagnosis; Disease
burden; Epidemiology; Skin cancer; Therapy;
Treatment
EVOLVING EPIDEMIOLOGY
AND BURDEN OF SKIN CANCER
The Increasing Incidence of Skin Cancer
Overall Skin Cancer
Skin cancer, including both malignant
melanoma (MM) and non-melanoma skin
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cancer (NMSC), represents the most common
malignancy in Caucasians [1–10]. The incidence
of both MM and NMSC is on the rise, with an
annual increase in MM of 0.6% among adults
over 50 years [11]. The estimated number of
new cases of skin melanoma in 2016 is 76,380,
which represents 4.5% of all new cancer cases
[12]. Deviations in reported incidence rates exist
and are attributed to varying risk factors
amongst different populations, as well as
discrepancies in national registration systems.
Furthermore, the incidence of melanoma may
be even higher than indicated, as the National
Cancer Registries has reported an
underestimation of its incidence in certain
countries [13].
Melanoma The increased incidence of
melanoma has not been accompanied by a
corresponding increase in mortality rates [12].
This has led to the question of whether there is
a true melanoma epidemic, or if the increased
incidence represents an epiphenomenon
attributable to over-diagnosis resulting from
intense screening and more biopsies.
The increased incidence of melanoma in the
USA involves all thickness groups (American
Joint Committee on Cancer tumor categories)
and is independent of socio-economic status
(a surrogate marker for access to care and
screening), suggesting that increased
screening and biopsy alone cannot account
for the dramatic change observed [14, 15]. This
finding is in agreement with the results
reported by Shaikh et al., who showed that
thickness increased in T3/T4 tumors and
nodular melanoma [16]. These observations
together ‘‘suggest that the melanoma epidemic
is real and not simply an artefact of increased
detection pressure of earlier-stage T1/T2
lesions’’ [16].
Conversely, there is evidence that
over-diagnosis may have a part to play. Recent
epidemiologic studies indicate that melanoma
in situ, with an annual incidence of 9.5% [12],
occupies a disproportionately high percentage
of the overall increase in MM incidence [17].
From the dermatopathologic point of view,
there are studies suggesting a current trend
towards reclassification of prior non-malignant
diagnoses as LL [18]. Furthermore, in a
population-based study correlating the number
of skin biopsies and the incidence of MM, the
investigators noted that there was a parallel
increase during a 15-year period, suggesting
that the MM epidemic may also be related to
increased scrutiny and number of biopsies [19].
Non-Melanoma Skin Cancer NMSC includes,
amongst others, Bowen’s disease, basal cell
carcinoma (BCC), and squamous cell
carcinoma (SCC). In Caucasians, the incidence
of NMSC is higher (by as much as 18–20 times)
than that of MM [20–22]. However, there are
significant limitations to NMSC epidemiology,
mainly attributed to marked geographic
variations in incidence rates, as well as to
exclusion of NMSC by large cancer registries
due to low mortality rates. Even secondary
analyses, whereby incidence data are extracted
from administrative healthcare databases, are
comparatively limited [23].
NMSC carries a substantial economic burden
[24, 25]. In Australia, it is the most costly
cancer, accounting for expenditure of
AUS$511 million in 2010 [24]. In the USA, it
has been estimated that total annual
NMSC-related expenditure is US$650 million,
with Medicare costs 6–7 times greater than
those for treating melanoma [26].
Reasons for Increased Incidence
of Skin Cancer
The observed increases in skin cancer rates
are associated with several factors, including
the transition toward significantly older
populations that are associated with a higher
risk of NMSC [27]. However, research has also
revealed the important role of increased
occupational and recreational UV light
exposure [22, 28]. For example, women
\40 years exhibited a constant linear increase
in BCC incidence rates of 6.3% between
1973 and 2009 [29], and studies have shown
that indoor tanning is associated with a
significantly increased risk of BCC and SCC,
with a higher risk with use in early life
(\25 years) [30].
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DIAGNOSTIC AND THERAPEUTIC
APPROACHES TO SKIN CANCER:
CHALLENGING CLINICAL CASES
Skin Cancer Diagnosis
A diagnosis of skin cancer needs consideration
of alternative diagnoses. Concerning actinic
keratosis, benign conditions include seborrheic
keratosis, verruca vulgaris, actinic
porokeratosis, O’Brien’s actinic granuloma,
eczema, lentigo solaris, lichen planus, or
psoriasis (Figs. 1, 2, 3), whereas malignant
conditions include SCC, Bowen’s disease,
BCC, lentigo maligna, keratoacanthoma, or
extramammary Paget’s disease.
Clinicians should ideally perform total body
skin examination (see Fig. 4 as an example case
of actinic keratosis appearing on the back of the
hand, as is often overlooked), at least for
high-risk individuals [31, 32]. The use of
non-invasive optical technologies, such as
optical coherence tomography (non-invasive
imaging test of the retina using light waves) or
dermatoscopy (imaging of the skin, allowing
statements concerning thickening of layers,
epidermal organization, and borders of a
lesion—in the case of actinic keratosis, the
typical honeycomb pattern may be observed),
may be helpful to improve diagnostic accuracy
in some skin cancers [33–37] (the case presented
in Fig. 5 may have benefitted from such
technologies, for example). Photodynamic
visualization (fluorescent visualization of skin
cancerization extension after preparation with
5-aminolaevulinic acid and subjection to
photodynamic therapy [light exposure]) might
also be beneficial for identification of actinic
keratosis, with histologic confirmation also
being necessary in cases in which invasive skin
cancer is suspected [38].
Treatment Challenges
Treatment strategies for skin cancers require
careful consideration, and there are many
challenges to overcome. However, with
increasing treatment choices, in terms of both
therapy combinations and sequences, we can
achieve better outcomes for patients with fewer
recurrences and longer treatment-free periods.
Field Cancerization and Non-Melanoma
Skin Cancer
Field cancerization of the skin, by which large
areas are affected by carcinogenic alternations,
presents various therapeutic challenges (Fig. 6).
Fig. 1 Case studies: 80-year-old woman presenting with field cancerization, and 45-year-old woman presenting with lupus
erythematodes (forehead and cheek shown)
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Owing to the difficulty in determining which
actinic keratosis lesions may progress to
invasive SCC, European guidelines recommend
that all lesions, or the affected field, are
treated [39]. For a patient with actinic
keratosis, there are three evolutionary
possibilities: spontaneous clearing; persistence;
or progression to invasive SCC [40].
Fig. 2 Case study: lichen planus complicating diagnosis in a 78-year-old man with actinic keratosis on his hand
Fig. 3 Case study: psoriasis complicating diagnosis in a 47-year-old man with actinic keratosis on his hand
Fig. 4 Case study: cheilitis actinica versus actinic keratosis (mouth and cheek shown)
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Approximately 60–65% of primary SCCs are
believed to have arisen from lesions previously
diagnosed clinically as actinic keratosis [41, 42],
and the rate at which a specific lesion may
become SCC is estimated to be a fraction of a
percent over the course of a year [43]. Even
when actinic keratosis lesions are classified
according to their clinical appearance, there is
little correlation with their histologic
classification, thereby reinforcing the need to
treat all actinic keratosis lesions and field
cancerization [44] (see ‘‘Cyclooxygenase in
Cancer Prevention and Treatments for Actinic
Keratosis’’, by Gareth Thomas and Colin
Morton, published in this Supplement, for
further details on actinic keratosis treatment).
While long-term efficacy and tolerance of
treatments are key considerations for
clinicians, comorbidities may impact
treatment success.
Fig. 5 Case study: 89-year-old woman presenting with multiple comorbidities (leg shown)
Fig. 6 Case study: field cancerization in an 80-year-old patient (head and shoulder/neck shown)
Dermatol Ther (Heidelb) (2017) 7 (Suppl 1):S5–S19 S9
The broad actinic keratosis spectrum
characterized by age, localization, medication,
co-dermatoses, and exogenous factors (Figs. 1, 5)
requires an individualized treatment approach
for each patient. Figures 1, 2, 3, 4, 5, 6, 7 and 8
show examples of clinical cases. Patients who
have received a kidney transplant represent a
particularly challenging population. Skin
tumors are a major problem in these patients,
and key challenges for the clinician include
treatment of the whole integument, sequential
therapies, and achievement of long-term success
when the patient is immunosuppressed
(where inflammatory and immunomodulatory
approaches are restricted). Figure 7 shows an
example of a transplant patient in whom there
was a suspicion of actinic keratoses in an
extended field, with treatment choices being
operative or destructive.
Many more therapeutic options are available
for non-immunosuppressed patients. However,
there is still limited availability of some
medications as they are not approved for
all NMSC types and localizations (Table 1).
Furthermore, when extensive field
cancerization encompassing the whole
integument is evident, treatment must occur
over a very large area of affected skin.
Fig. 7 Case study: Treatment of a patient who had received a kidney transplant (leg shown)
Fig. 8 Case study: 85-year-old woman with multiple basal cell carcinomas (forehead shown)
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Basal Cell Carcinoma
Though the majority of patients with BCC have
a good prognosis, some patients develop a more
complex, advanced disease with relatively few
treatment options; indeed, no formal treatment
algorithms are available. However, the recent
development of hedgehog signaling pathway
inhibitors, such as vismodegib, has been
significant, providing an effective treatment
option for some patients. In particular,
vismodegib treatment may be appropriate if
the tumor is considered inoperable and
radiation therapy is declined; complete
remission is achieved in 21% of locally
advanced BCC [45], even in those infiltrating
adjacent muscle and bone structures. Many
more cases with partial remission and
shrinking tumors may be considered for
operation (Fig. 8).
Malignant Melanoma Stage IV
Treatment approaches for melanoma
encompass two main strategies: targeted
therapies (e.g., BRAF- and MEK-inhibitors);
and immunotherapies (e.g., anti-CTLA-4
and anti-PD-1).
The combination of BRAF- and
MEK-inhibitors is well established in patients
with tumors harboring the BRAF mutation,
primarily owing to the development of tumor
resistance with BRAF-inhibitor monotherapy
[46]. Although this combination represents an
effective option with an acceptable toxicity
profile [47], questions still remain as to
whether sequential or cyclic application of
BRAF- and MEK-inhibitors would be more
beneficial, and whether immunotherapies may
represent equally useful alternatives [48].
With regard to immunotherapies, anti-PD-1
monotherapy may be preferable to anti-CLTA-4
monotherapy [49]: combining anti-PD-1 and
anti-CTLA-4 therapies may increase response and
remission rates. However, this may be at the risk of
higher toxicity (with predominantly
gastrointestinal, hepatic, and cutaneous adverse
events) [50] and therefore would be most
appropriate in patients with progressive disease
or lower PD-L1 expression. Further studies on
sequential/cyclic combinations of these
immunotherapies with consideration of
immunologically relevant parameters (e.g., PD-L1
expression levels, BRAF/NRAS/cKIT mutation
analysis), tumor typing and staging, and patient
characteristics (e.g., age, comorbidities, treatment
history) are ongoing [48].
Table 1 Recommended topical treatments for actinic keratosis
Drug EMA approval date Approved for localization Area
5% 5-FUa [92] 1998 All localizations 500 cm2
5-FU 0.5% with 10% salicylic
acidb [93]
2011 All localizations 25 cm2 (maximum of 10 lesions)
3% diclofenac with 2.5% hyaluronic
acidb [94]
2000 All localizations Maximum of 8 g/day
5% imiquimoda [95] 1998 Head 25 cm2
3.75% imiquimoda [96] 2012 Head 25 cm2
0.05% ingenol mebutatec [97] 2012 Body, extremities 25 cm2
0.015% ingenol mebutatec [98] 2012 Head 25 cm2
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THE SUN: FRIEND OR FOE?
The Impact of Sunlight Exposure
on Health
The impact of sunlight exposure on health is
subject to debate—here, we present our views
on the available evidence. Several
epidemiologic studies have provided evidence
for the beneficial effect of sun exposure on
overall health status. All-cause mortality (death
due to any cause) was inversely correlated with
increased sun exposure in several studies, with a
particular reduction in cardiovascular mortality.
A nationwide Danish case–control study
showed that having a diagnosis of skin cancer,
a marker for sun exposure, was associated with a
lower incidence of myocardial infarction, fewer
hip fractures in those below the age of 90 years,
and fewer deaths from any cause [51]. Similarly,
among Swedish women, habits indicating
avoidance of sun exposure were a risk factor
for all-cause mortality; the mortality rate among
such ‘avoiders’ was approximately two-fold
higher compared with the highest sun
exposure group [52]. It is possible that severely
restricting sun exposure, particularly at
locations with low solar intensity, might in
fact have a negative effect on health [52].
In addition, studies have shown that blood
pressure and the incidence of ischemic heart
disease correlate with the latitude of a person’s
country of residence [53, 54]. It is also known
that blood pressure is lower during summer
compared with winter [55]. This is of great
significance as high blood pressure is the
leading cause of disease and premature death
in the world [56, 57].
Meta-analyses of several studies indicate
that serum vitamin D levels are inversely
correlated with blood pressure and the
incidence of cardiovascular disease, diabetes,
and hypertension [58, 59]. Furthermore,
observational studies indicate that the risk of
death from any cause is correlated with
circulating 25-hydroxyvitamin D [60].
However, extensive studies, comprising
meta-analyses of several clinical trials, have
conclusively shown that oral vitamin D
supplementation has no effect on blood
pressure, ischemic heart disease, or stroke
[58, 61], although vitamin D3 supplementation
may reduce all-cause mortality [60]. Although
vitamin D may account for some of the
beneficial effects observed with sunlight
exposure, it may be considered a marker of the
person’s occupational or recreational sun
exposure.
Nitric Oxide and the Skin as a Mechanism
Behind the Positive Effects of Sunlight
It has been proposed that many of the
documented beneficial effects of exposure
to sunlight, particularly those related to
cardiovascular health, involve mechanisms
unrelated to melatonin, vitamin D, and
exposure to UVB [62]. Recent studies suggest
that stores of nitric oxide (NO)-related species in
the skin may be particularly important in this
respect. Both the skin and the dermal
vasculature contain biologically significant
stores of bound NO species [63]. Upon
exposure of the skin to UVA,
photodecomposition of these NO stores takes
place and NO species are released into the
circulation, resulting in arterial vasodilation,
with cardioprotective and antihypertensive
effects [62, 64]. This mechanism has also been
shown to suppress the development of diabetes
and metabolic syndrome in a mouse model [65].
Long-term suberythemal and erythemal UV
light significantly suppressed weight gain,
glucose intolerance, and insulin resistance in
mice fed a high-fat diet, an effect that was not
reproduced by vitamin D supplementation.
Importantly, skin induction of NO reproduced




There are several key areas in which knowledge
of HPV natural history and vaccination status is
important for dermatologists. Table 2 provides
examples of common questions, along with
evidence-based responses for each question.
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Table 2 What should the dermatologist know about HPV? Key questions and answers
Question Answer
Does every patient develop genital warts after HPV
infection?
Even though HPV infection is very common, very few
patients will develop genital warts after infection
How long can HPV infections last? Up to 90% of HPV infections will clear within 2 years
Is a patient with subclinical infection contagious? Yes, but we should distinguish between subclinical and latent
infections (we know very little about latent infections).
subclinical infections do exist and can last for years, but
they are probably only contagious when there is viral
replication and shedding
Is the patient no longer infectious once genital warts have
been treated?
Patients can be infectious even after removal/treatment of
genital warts
Is there a rationale for treating subclinical HPV infections? No, what is important is the lesions, not the infection itself
What should be the advice for patients who have been
treated for genital warts, but who may still have subclinical
infection?
The important thing to focus on is the lesions; screening for
early lesions, and subsequent treatment
Although there is no formal recommendation, HPV
vaccination is advised among patients with a history of
HPV-related lesions
What advice should patients receive for their sexual partners
concerning infection?
The important thing to focus on is the lesions; screening for
early lesions, and subsequent treatment
Although there is no formal recommendation, HPV
vaccination is advised among patients with a history of
HPV-related lesions
Is there any risk of HPV-related cancer in male patients? Only patients who do not resolve HPV infections are at a
higher risk of HPV persistence and subsequent
HPV-related diseases, including pre-cancer and cancer
Do HPV vaccines protect against other HPV genotypes that
may cause genital warts?
Yes, they protect against HPV types 6 and 11 that cause 90%
of genital warts and recurrent respiratory papillomatosis
Considering the cost of the vaccine, is there enough evidence
for vaccination of already infected patients? And for their
sexual partners?
The current cost of HPV vaccines in national immunization
programs has been reduced threefold
Yes, the vaccine will not cure current active infections but
will block new infections as well as auto-inoculated virions
Is there a rationale for HPV vaccination in young males? Yes, very strong, and threefold:
1. To reduce transmission and circulation in the population
2. To protect themselves (male burden is now considerable)
3. For gender equality
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Human Papillomavirus and Cancer
More than 150 human papillomavirus (HPV)
types have so far been identified. HPV falls into
five genera, with the Alpha and Beta/Gamma
genera representing the largest groups [66].
Mucosal HPV types from the Alpha genus are
the ones associated with neoplastic disease and
the most common viral infections of the
reproductive tract; the World Health
Organization acknowledges that most sexually
active men and women will be infected at some
point in their lives [67]. Twelve Alpha HPVs
are classified as carcinogenic to humans and
fifteen as probably/possibly carcinogenic [68].
Two HPVs, HPV 16 and 18, stand out for
their carcinogenicity and contribute to
approximately 70% of all HPV-related cancers
worldwide [69–74]. Although most infections
resolve spontaneously and the majority of
women with infection do not develop cancer,
a small proportion of HPV infections will persist
and progress to pre-cancer and cancer [75].
Protective risk factors that reduce the risk of
HPV infection and subsequent cancer include
consistent condom use [76], male circumcision
[77], and use of an intrauterine device [78].
The impact of the estimated contribution of
HPV to cancer from an epidemiologic point of
view is larger than previously thought. Indeed,
HPV infection can be considered a pandemic
disease for several reasons [79]. Firstly, it is
universal and widespread, occurring on all
continents, in both women and men, among
young people and adults, and across most races
and socioeconomic groups. Secondly, it is
extensive, as it causes a variety of related
diseases, both pre-cancerous and cancerous,
involving a wide range of anatomic sites.
Finally, the epidemiology of HPV is dynamic,
as opposed to stable, with increasing rates of
infection and disease.
The Role of HPV in Skin Cancer
Some studies suggest that a particular genus, the
b HPVs, may play a role in the pathogenesis of
NMSC [80], though this role has not been well
studied. However, the association of b HPV
infection with NMSC in patients with a very
rare, genetically determined condition,
epidermodysplasia verruciformis, has been well
established [81]. In stark contrast to
a HPV-associated cancers (such as cervical
cancer, as discussed above), the presence of
b-HPV DNA does not appear to be essential




Three HPV vaccines are commercially
available including a bivalent form against
HPV types 16 and 18, a quadrivalent form
against HPV types 6, 11, 16 and 18, and a
9-valent form against types 6, 11, 16, 18, 31,
33, 45, 52 and 58 [83]. Persistent infection
with high-risk HPV types 16 and 18 is
responsible for the majority of cervical
cancer worldwide, whereas low-risk types 6
and 11 are responsible for most genital warts
[84]. The vaccines are highly efficacious,
immunogenic and safe in the prevention of
pre- and neoplastic cervical-, vulvar-, vaginal-
or anal-related disease in women [85–87]. The
quadrivalent HPV vaccine has been shown to
be effective against genital warts [88, 89] and
anal precancerous lesions [90]. As well as
being associated with wart formation,
cutaneous papillomaviruses can lead to the
development of NMSC, but further research
with HPV vaccines is needed to assess their
efficacy in preventing NMSC.
Data from multiple countries have shown a
clear impact in the reduction of HPV infections
and related conditions within a few years of
vaccine introduction [91], and pediatricians,
gynecologists, primary healthcare professionals,
clinicians, and public health officials, as well as
dermatologists, have all played a key role in
achieving this wide vaccination coverage.
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
S14 Dermatol Ther (Heidelb) (2017) 7 (Suppl 1):S5–S19
ACKNOWLEDGEMENTS
Sponsorship and article processing charges for
this supplement were funded by Almirall S.A.
This article is based on presentations from the
9th Skin Academy Symposium, April 9–10,
2016, Barcelona, Spain, sponsored by
Almirall S.A. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
manuscript, take responsibility for the integrity
of the work as a whole, and have given final
approval to the version to be published. We
thank Dr Laia Bruni for her advice and
contribution to this manuscript, on behalf of
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